Copyright © Inderes 2011 - present. All rights reserved.
Log in to receive notifications.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Camurus

538

 

SEK

 

-13.44 %

Less than 1K followers

CAMX

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus
-13.44%
-4.27%
-9.43%
-4.86%
-11.59%
-4.27%
+200.56%
+327.66%
+790.35%

Camurus operates in biotechnology. The company runs as a research-based pharmaceutical company and develops and distributes products for the treatment of severe and chronic diseases. Diseases treated with the company's products include, for example, cancer, endocrine disorders, and patients with opioid dependence. Camurus runs development projects under its own auspices and in partnership with international pharmaceutical companies. The company is headquartered in Lund.

Read more
Market cap
31.68B SEK
Turnover
327.26M SEK
Revenue
1.87B
EBIT %
25.12 %
P/E
72.8
Dividend yield-%
-
Financial calendar
15.5
2025

Interim report Q1'25

27.5
2025

General meeting '25

17.7
2025

Interim report Q2'25

All
Webcasts
Press releases
ShowingAll content types
Camurus, Audiocast with teleconference, Q1'25
Webcast12 minutes ago

Camurus, Audiocast with teleconference, Q1'25

Camurus
Regulatory press release7 hours ago

Camurus AB: Camurus' Interim Report January-March 2025

Camurus
Regulatory press releaseyesterday

Camurus AB: Camurus appoints Anders Vadsholt as Chief Financial Officer

Camurus

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release4/30/2025, 8:00 AM

Camurus AB: Camurus Annual Report for 2024

Camurus
Regulatory press release4/25/2025, 2:00 PM

Camurus AB: CHMP recommends approval of Oczyesa® for treatment of acromegaly in the EU

Camurus
Press release4/24/2025, 11:39 AM

Redeye: Camurus - A Swedish Biotech Success Story

Camurus
Regulatory press release4/23/2025, 6:00 AM

Notice of annual general meeting 2025 in Camurus AB (publ)

Camurus
Press release3/19/2025, 7:00 AM

Camurus AB: Camurus' CEO Fredrik Tiberg receives The Arthur D. Little Nordic Life Science Award

Camurus
Press release3/3/2025, 10:00 AM

Camurus AB: Jon Garay Alonso will leave position as Camurus' CFO

Camurus
Camurus, Audiocast with teleconference, Q4'24
Webcast2/13/2025, 1:00 PM

Camurus, Audiocast with teleconference, Q4'24

Camurus
Regulatory press release2/13/2025, 6:00 AM

Camurus AB: Camurus' Full Year Report 2024

Camurus
Regulatory press release1/23/2025, 1:30 PM

Camurus AB: Camurus' fourth quarter and full year 2024 earnings above previous estimates

Camurus
Regulatory press release12/30/2024, 6:00 AM

Camurus AB: Change in number of shares and votes in Camurus

Camurus
Regulatory press release11/12/2024, 6:00 AM

Camurus AB: Camurus' Nomination Committee appointed for the Annual General Meeting 2025

Camurus
Press release11/11/2024, 9:00 AM

Camurus AB: Camurus to present at Jefferies London Healtcare Conference

Camurus
Camurus, Audiocast with teleconference, Q3'24
Webcast11/7/2024, 1:00 PM

Camurus, Audiocast with teleconference, Q3'24

Camurus
Regulatory press release11/7/2024, 6:00 AM

Camurus AB: Camurus' Interim Report Third Quarter 2024

Camurus
Regulatory press release10/21/2024, 11:00 PM

Camurus AB: Camurus provides regulatory update on the US NDA for CAM2029 in acromegaly

Camurus
Regulatory press release9/30/2024, 5:00 AM

Camurus AB: Change in number of shares and votes in Camurus

Camurus
Press release9/20/2024, 6:00 AM

Camurus AB: EMA positive opinion for orphan drug designation to Camurus' octreotide SC depot for the treatment of polycystic liver disease

Camurus
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team

Privacy preferences

Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.